anmelden
SLI
2.304,26
PKT
-14,05
PKT
-0,61
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 05.02.21 | ABB (Asea Brown Boveri) Sell | Deutsche Bank AG | |
| 04.02.21 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 04.02.21 | Roche Outperform | Bernstein Research | |
| 04.02.21 | ABB (Asea Brown Boveri) Sell | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
| 04.02.21 | Roche buy | Jefferies & Company Inc. | |
| 04.02.21 | ABB (Asea Brown Boveri) Underperform | Jefferies & Company Inc. | |
| 04.02.21 | Roche Conviction Buy List | Goldman Sachs Group Inc. | |
| 04.02.21 | ABB (Asea Brown Boveri) Underweight | JP Morgan Chase & Co. | |
| 04.02.21 | Holcim buy | Goldman Sachs Group Inc. | |
| 03.02.21 | Nestlé buy | UBS AG | |
| 03.02.21 | Novartis buy | UBS AG | |
| 03.02.21 | Novartis Underweight | JP Morgan Chase & Co. | |
| 02.02.21 | Givaudan Underperform | Jefferies & Company Inc. | |
| 02.02.21 | Givaudan Sell | Goldman Sachs Group Inc. | |
| 02.02.21 | Givaudan buy | UBS AG | |
| 02.02.21 | Holcim overweight | JP Morgan Chase & Co. | |
| 02.02.21 | Zurich Insurance Underperform | Oddo BHF | |
| 01.02.21 | Givaudan Neutral | JP Morgan Chase & Co. | |
| 01.02.21 | Holcim Outperform | Credit Suisse Group | |
| 01.02.21 | Zurich Insurance Hold | Jefferies & Company Inc. | |
| 01.02.21 | Givaudan Hold | Deutsche Bank AG | |
| 01.02.21 | Givaudan Underperform | Bernstein Research | |
| 01.02.21 | Givaudan Underperform | Credit Suisse Group | |
| 29.01.21 | Givaudan Neutral | JP Morgan Chase & Co. | |
| 29.01.21 | Givaudan add | Baader Bank | |
| 29.01.21 | Givaudan Underperform | Bernstein Research | |
| 28.01.21 | Roche Neutral | JP Morgan Chase & Co. | |
| 28.01.21 | Swiss Re overweight | JP Morgan Chase & Co. | |
| 27.01.21 | Givaudan buy | UBS AG | |
| 27.01.21 | Zurich Insurance Sector Perform | RBC Capital Markets | |
| 27.01.21 | Swiss Re Outperform | RBC Capital Markets | |
| 27.01.21 | UBS buy | Kepler Cheuvreux | |
| 27.01.21 | UBS buy | Goldman Sachs Group Inc. | |
| 27.01.21 | UBS overweight | JP Morgan Chase & Co. | |
| 27.01.21 | Novartis Neutral | Credit Suisse Group | |
| 27.01.21 | UBS Outperform | Credit Suisse Group | |
| 27.01.21 | UBS Underweight | Barclays Capital | |
| 26.01.21 | Roche buy | Goldman Sachs Group Inc. | |
| 26.01.21 | UBS Neutral | UBS AG | |
| 26.01.21 | Novartis buy | UBS AG |
